Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Aaron C. Tan, Keigo Kobayashi, Stephanie P.L. Saw, Daniel S.W. Tan & Darren Wan-Teck Lim. (2023) Immunotherapy with chemotherapy and anti-angiogenic therapy for EGFR mutated NSCLC: challenging the dogma. Expert Review of Anticancer Therapy 23:2, pages 117-120.
Read now
Read now
Sakunie Sawai, Pooi-Fong Wong & Thamil Selvee Ramasamy. (2022) Hypoxia-regulated microRNAs: the molecular drivers of tumor progression. Critical Reviews in Biochemistry and Molecular Biology 57:4, pages 351-376.
Read now
Read now
Daniel Ahn, Daniel Walden & Tanios Bekaii-Saab. (2022) Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer. Expert Opinion on Investigational Drugs 31:5, pages 437-441.
Read now
Read now
Mario Vaccaro, Fabrizio Guarneri, Francesco Borgia, Andrea Pollicino, Giuseppe Altavilla & Serafinella P. Cannavò. (2016) Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer. Journal of Dermatological Treatment 27:2, pages 148-152.
Read now
Read now
Feng Jin, Hui Zhu, Li Kong & Jinming Yu. (2015) A spectrum of cutaneous toxicities from erlotinib may be a robust clinical marker for non-small-cell lung therapy: a case report and literature review. OncoTargets and Therapy 8, pages 943-946.
Read now
Read now
Articles from other publishers (21)
Yunhang Guo, Nan Hu, Ye Liu, Wei Zhang, Desheng Yu, Gongyin Shi, Bo Zhang, Longbo Yin, Min Wei, Xi Yuan, Lusong Luo, Fan Wang, Xiaomin Song, Lei Xin, Qiang Wei, Yong Li, Ying Guo, Shuaishuai Chen, Taichang Zhang, Shuo Zhang, Xing Zhou, Cuining Zhang, Dan Su, Junhua Liu, Zhenzhen Cheng, Jiye Zhang, Haimei Xing, Hanzi Sun, Xin Li, Yuan Zhao, Min He, Yue Wu, Yin Guo, Xuebing Sun, Alice Tian, Changyou Zhou, Steve Young, Xuesong Liu, Lai Wang & Zhiwei Wang. (2023) Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases. Journal of Medicinal Chemistry 66:6, pages 4025-4044.
Crossref
Crossref
Yuankai Shi, Jianying Zhou, Yanqiu Zhao, Bo Zhu, Liangming Zhang, Xingya Li, Jian Fang, Jianhua Shi, Zhixiang Zhuang, Sheng Yang, Donglin Wang, Huiqing Yu, Longzhen Zhang, Rongsheng Zheng, Michael Greco & Tingting Wang. (2023) Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study. BMC Medicine 21:1.
Crossref
Crossref
Pingxin Zhang, Ren Mao, Chuhan Zhang, Yun Qiu & Minhu Chen. (2023) Gastrointestinal injury induced by immunomodulators: A review article. Therapeutic Advances in Gastroenterology 16, pages 175628482311585.
Crossref
Crossref
Naohiro Sekiguchi, Shinya Rai, Wataru Munakata, Kenshi Suzuki, Hiroshi Handa, Hirohiko Shibayama, Tomoyuki Endo, Yasuhito Terui, Noriko Iwaki, Noriko Fukuhara, Hiro Tatetsu, Shinsuke Iida, Takayuki Ishikawa, Daisuke Iguchi & Koji Izutsu. (2022) Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia. Cancer Science 113:6, pages 2085-2096.
Crossref
Crossref
Dou Dou, Wenjie Sha, Yanyan Diao, Rongrong Su, Yunjin Qiao, Zhixiao Yu, Zhenjiang Zhao, Honglin Li, Zhuo Chen & Yufang Xu. (2022) Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton’s tyrosine kinase (BTK) inhibitors. Bioorganic Chemistry 119, pages 105541.
Crossref
Crossref
Cecilia C. Ayala-Aguilera, Teresa Valero, Álvaro Lorente-Macías, Daniel J. Baillache, Stephen Croke & Asier Unciti-Broceta. (2021) Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis. Journal of Medicinal Chemistry 65:2, pages 1047-1131.
Crossref
Crossref
Layla Al-mansoori, Philip Elsinga & Sayed K. Goda. (2021) Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy. Biomedicine & Pharmacotherapy 144, pages 112260.
Crossref
Crossref
H. Yesid Estupiñán, Anna Berglöf, Rula Zain & C. I. Edvard Smith. (2021) Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Jingyi Ding, Magdoleen Farah, Tarek Nayfeh, Konstantinos Malandris, Apostolos Manolopoulos, Pamela Ginex, Bashar Hasan, Hayley Dunnack, Rami Abd-Rabu, Moutie Rajjoub, Larry Prokop, Rebecca Morgan & M. Hassan Murad. (2020) Targeted Therapy– and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis. Oncology Nursing Forum 47:5, pages E149-E160.
Crossref
Crossref
Daniela Angst, François Gessier, Philipp Janser, Anna Vulpetti, Rudolf Wälchli, Christian Beerli, Amanda Littlewood-Evans, Janet Dawson, Barbara Nuesslein-Hildesheim, Grazyna Wieczorek, Sascha Gutmann, Clemens Scheufler, Alexandra Hinniger, Alfred Zimmerlin, Enrico G. Funhoff, Robert Pulz & Bruno Cenni. (2020) Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase. Journal of Medicinal Chemistry 63:10, pages 5102-5118.
Crossref
Crossref
Dorothy M K Keefe & Emma H Bateman. (2019) Potential Successes and Challenges of Targeted Cancer Therapies. JNCI Monographs 2019:53.
Crossref
Crossref
H.-T. Arkenau, A. Italiano, G. Mak, M. Toulmonde, R.D. Baird, J. Garcia-Corbacho, R. Plummer, M. Flynn, M. Forster, R.H. Wilson, D. Tosi, A. Adenis, K. Donaldson, J. Posner, I. Kawabata, A. Arimura, S. Deva & J. Spicer. (2018) An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. European Journal of Cancer 103, pages 17-23.
Crossref
Crossref
Oi Kwan Wong, Thomas-Toan Tran, Wei-Hsien Ho, Meritxell Galindo Casas, Melinda Au, Marjorie Bateman, Kevin C. Lindquist, Arvind Rajpal, David L. Shelton, Pavel Strop & Shu-Hui Liu. (2018) RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models. Oncotarget 9:71, pages 33446-33458.
Crossref
Crossref
G. Milano, F. Innocenti, B. Lacarelle & J. Ciccolini. (2018) “No pain, No gain” still true with immunotherapy: When the finger shows the moon, look at the moon!. Critical Reviews in Oncology/Hematology 127, pages 1-5.
Crossref
Crossref
Rosalin Mishra, Ariella B. Hanker & Joan T. Garrett. (2017) Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget 8:69, pages 114371-114392.
Crossref
Crossref
Stacy L. Moulder, Virginia F. Borges, Tara Baetz, Tessa Mcspadden, Gina Fernetich, Rashmi K. Murthy, Renae Chavira, Kari Guthrie, Emma Barrett & Stephen K. Chia. (2017) Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC). Clinical Cancer Research 23:14, pages 3529-3536.
Crossref
Crossref
Martin Wallner, Sabine Köck-Hódi, Shaina Booze, Kathryn White & Hanna Mayer. (2016) Nursing Management of Cutaneous Toxicities From Epidermal Growth Factor Receptor Inhibitors. Clinical Journal of Oncology Nursing 20:5, pages 529-536.
Crossref
Crossref
D. Jenni, M.B. Karpova, B. Mühleisen, J. Mangana, J. Dreier, J. Hafner & R. Dummer. (2016) A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis. ESMO Open 1:1, pages e000003.
Crossref
Crossref
Zheng Xu & Lu Cai. (2015) Diabetic cardiomyopathy: Role of epidermal growth factor receptor tyrosine kinase. Journal of Molecular and Cellular Cardiology 84, pages 10-12.
Crossref
Crossref
T E Webb, A Hughes, D S Smalley & K A Spriggs. (2015) An internal ribosome entry site in the 5′ untranslated region of epidermal growth factor receptor allows hypoxic expression. Oncogenesis 4:1, pages e134-e134.
Crossref
Crossref
Solange Peters, Stefan Zimmermann & Alex A. Adjei. (2014) Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions. Cancer Treatment Reviews 40:8, pages 917-926.
Crossref
Crossref